$QURE

Kapusta Matthew C sold $9.4M of QURE

Kapusta Matthew C (CEO, Managing Director) sold 206,100 shares of uniQure N.V. (QURE) at an average of $45.47 ($42.61–$50.00, $9.37M total) across 8 trades over 2026-06-17 to 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kapusta Matthew C
Published Jun 22, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest fact is the CEO’s $9.37M open-market sale executed across 8 trades (2026-06-17 to 2026-06-18) with a stated 10b5-1 plan.

02

Market read

Provides a concrete, time-stamped insider selling datapoint that can influence short-term sentiment but lacks a fundamental trigger in the text.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent positive catalysts (not present here) or follow-on insider buying (not disclosed in this text).

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-06-22)

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure CEO Matthew C Kapusta sold $9.37M of QURE shares via an open-market sale under a pre-arranged 10b5-1 plan (Form 4 filed today).

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source Form 4 showing a large sale, yet it explicitly references a pre-arranged 10b5-1 plan, which typically reduces interpretive signal about new information.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated; uniQure is the only subject.

None indicated beyond potential sentiment for the single issuer.

Counterpoint

Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect routine liquidity rather than bearish expectations.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • Kapusta Matthew C

    CEO, Managing Director; reported open-market sale of QURE shares.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as the basis for the insider’s sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.